Cargando…

Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach

BACKGROUND: Artemisinin-resistant falciparum malaria has emerged in Southeast Asia, posing a major threat to malaria control. It is characterised by delayed asexual-stage parasite clearance, which is the reference comparator for the molecular marker ‘Kelch 13’ and in vitro sensitivity tests. However...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Lisa J., Flegg, Jennifer A., Phyo, Aung Pyae, Wiladpai-ngern, Ja Hser, Bethell, Delia, Plowe, Christopher, Anderson, Tim, Nkhoma, Standwell, Nair, Shalini, Tripura, Rupam, Stepniewska, Kasia, Pan-Ngum, Wirichada, Silamut, Kamolrat, Cooper, Ben S., Lubell, Yoel, Ashley, Elizabeth A., Nguon, Chea, Nosten, François, White, Nicholas J., Dondorp, Arjen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412633/
https://www.ncbi.nlm.nih.gov/pubmed/25919029
http://dx.doi.org/10.1371/journal.pmed.1001823
_version_ 1782368695110074368
author White, Lisa J.
Flegg, Jennifer A.
Phyo, Aung Pyae
Wiladpai-ngern, Ja Hser
Bethell, Delia
Plowe, Christopher
Anderson, Tim
Nkhoma, Standwell
Nair, Shalini
Tripura, Rupam
Stepniewska, Kasia
Pan-Ngum, Wirichada
Silamut, Kamolrat
Cooper, Ben S.
Lubell, Yoel
Ashley, Elizabeth A.
Nguon, Chea
Nosten, François
White, Nicholas J.
Dondorp, Arjen M.
author_facet White, Lisa J.
Flegg, Jennifer A.
Phyo, Aung Pyae
Wiladpai-ngern, Ja Hser
Bethell, Delia
Plowe, Christopher
Anderson, Tim
Nkhoma, Standwell
Nair, Shalini
Tripura, Rupam
Stepniewska, Kasia
Pan-Ngum, Wirichada
Silamut, Kamolrat
Cooper, Ben S.
Lubell, Yoel
Ashley, Elizabeth A.
Nguon, Chea
Nosten, François
White, Nicholas J.
Dondorp, Arjen M.
author_sort White, Lisa J.
collection PubMed
description BACKGROUND: Artemisinin-resistant falciparum malaria has emerged in Southeast Asia, posing a major threat to malaria control. It is characterised by delayed asexual-stage parasite clearance, which is the reference comparator for the molecular marker ‘Kelch 13’ and in vitro sensitivity tests. However, current cut-off values denoting slow clearance based on the proportion of individuals remaining parasitaemic on the third day of treatment ('day-3'), or on peripheral blood parasite half-life, are not well supported. We here explore the parasite clearance distributions in an area of artemisinin resistance with the aim refining the in vivo phenotypic definitions. METHODS AND FINDINGS: Data from 1,518 patients on the Thai-Myanmar and Thai-Cambodian borders with parasite half-life assessments after artesunate treatment were analysed. Half-lives followed a bimodal distribution. A statistical approach was developed to infer the characteristics of the component distributions and their relative contribution to the composite mixture. A model representing two parasite subpopulations with geometric mean (IQR) parasite half-lives of 3.0 (2.4-3.9) hours and 6.50 (5.7-7.4) hours was consistent with the data. For individual patients, the parasite half-life provided a predicted likelihood of an artemisinin-resistant infection which depends on the population prevalence of resistance in that area. Consequently, a half-life where the probability is 0.5 varied between 3.5 and 5.5 hours. Using this model, the current 'day-3' cut-off value of 10% predicts the potential presence of artemisinin-resistant infections in most but not all scenarios. These findings are relevant to the low-transmission setting of Southeast Asia. Generalisation to a high transmission setting as in regions of Sub-Saharan Africa will need additional evaluation. CONCLUSIONS: Characterisation of overlapping distributions of parasite half-lives provides quantitative insight into the relationship between parasite clearance and artemisinin resistance, as well as the predictive value of the 10% cut-off in 'day-3' parasitaemia. The findings are important for the interpretation of in vitro sensitivity tests and molecular markers for artemisinin resistance and for contextualising the ‘day 3’ threshold to account for initial parasitaemia and sample size.
format Online
Article
Text
id pubmed-4412633
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44126332015-05-12 Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach White, Lisa J. Flegg, Jennifer A. Phyo, Aung Pyae Wiladpai-ngern, Ja Hser Bethell, Delia Plowe, Christopher Anderson, Tim Nkhoma, Standwell Nair, Shalini Tripura, Rupam Stepniewska, Kasia Pan-Ngum, Wirichada Silamut, Kamolrat Cooper, Ben S. Lubell, Yoel Ashley, Elizabeth A. Nguon, Chea Nosten, François White, Nicholas J. Dondorp, Arjen M. PLoS Med Research Article BACKGROUND: Artemisinin-resistant falciparum malaria has emerged in Southeast Asia, posing a major threat to malaria control. It is characterised by delayed asexual-stage parasite clearance, which is the reference comparator for the molecular marker ‘Kelch 13’ and in vitro sensitivity tests. However, current cut-off values denoting slow clearance based on the proportion of individuals remaining parasitaemic on the third day of treatment ('day-3'), or on peripheral blood parasite half-life, are not well supported. We here explore the parasite clearance distributions in an area of artemisinin resistance with the aim refining the in vivo phenotypic definitions. METHODS AND FINDINGS: Data from 1,518 patients on the Thai-Myanmar and Thai-Cambodian borders with parasite half-life assessments after artesunate treatment were analysed. Half-lives followed a bimodal distribution. A statistical approach was developed to infer the characteristics of the component distributions and their relative contribution to the composite mixture. A model representing two parasite subpopulations with geometric mean (IQR) parasite half-lives of 3.0 (2.4-3.9) hours and 6.50 (5.7-7.4) hours was consistent with the data. For individual patients, the parasite half-life provided a predicted likelihood of an artemisinin-resistant infection which depends on the population prevalence of resistance in that area. Consequently, a half-life where the probability is 0.5 varied between 3.5 and 5.5 hours. Using this model, the current 'day-3' cut-off value of 10% predicts the potential presence of artemisinin-resistant infections in most but not all scenarios. These findings are relevant to the low-transmission setting of Southeast Asia. Generalisation to a high transmission setting as in regions of Sub-Saharan Africa will need additional evaluation. CONCLUSIONS: Characterisation of overlapping distributions of parasite half-lives provides quantitative insight into the relationship between parasite clearance and artemisinin resistance, as well as the predictive value of the 10% cut-off in 'day-3' parasitaemia. The findings are important for the interpretation of in vitro sensitivity tests and molecular markers for artemisinin resistance and for contextualising the ‘day 3’ threshold to account for initial parasitaemia and sample size. Public Library of Science 2015-04-28 /pmc/articles/PMC4412633/ /pubmed/25919029 http://dx.doi.org/10.1371/journal.pmed.1001823 Text en © 2015 White et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
White, Lisa J.
Flegg, Jennifer A.
Phyo, Aung Pyae
Wiladpai-ngern, Ja Hser
Bethell, Delia
Plowe, Christopher
Anderson, Tim
Nkhoma, Standwell
Nair, Shalini
Tripura, Rupam
Stepniewska, Kasia
Pan-Ngum, Wirichada
Silamut, Kamolrat
Cooper, Ben S.
Lubell, Yoel
Ashley, Elizabeth A.
Nguon, Chea
Nosten, François
White, Nicholas J.
Dondorp, Arjen M.
Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title_full Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title_fullStr Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title_full_unstemmed Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title_short Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach
title_sort defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412633/
https://www.ncbi.nlm.nih.gov/pubmed/25919029
http://dx.doi.org/10.1371/journal.pmed.1001823
work_keys_str_mv AT whitelisaj definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT fleggjennifera definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT phyoaungpyae definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT wiladpaingernjahser definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT bethelldelia definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT plowechristopher definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT andersontim definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT nkhomastandwell definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT nairshalini definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT tripurarupam definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT stepniewskakasia definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT panngumwirichada definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT silamutkamolrat definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT cooperbens definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT lubellyoel definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT ashleyelizabetha definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT nguonchea definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT nostenfrancois definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT whitenicholasj definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach
AT dondorparjenm definingtheinvivophenotypeofartemisininresistantfalciparummalariaamodellingapproach